Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 15/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174492 | 0.82 | OPRM1 (0.43) | OPRM1OPRL1OPRD1OPRK1NPSR1 | |
| SCHEMBL4173900 | 0.82 | OPRL1 (0.56) | OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL6777765 | 0.79 | OPRM1 (0.57) | OPRM1OPRL1OPRD1OPRK1CYP2D6 | |
| SCHEMBL6895386 | 0.78 | OPRM1 (0.43) | OPRM1OPRL1OPRD1OPRK1NPSR1 | |
| SCHEMBL6778892 | 0.74 | OPRM1 (0.56) | OPRM1OPRL1OPRD1OPRK1NPSR1 | |
| SCHEMBL6774471 | 0.73 | OPRK1 (0.48) | OPRM1OPRL1OPRD1OPRK1NPSR1 | |
| SCHEMBL15797515 | 0.72 | NPSR1 (0.57) | OPRM1OPRL1OPRD1OPRK1NPSR1 | |
| SCHEMBL6889358 | 0.71 | OPRM1 (0.54) | OPRM1OPRL1OPRD1OPRK1NPSR1 | |
| SCHEMBL10047375 | 0.68 | NPSR1 (0.61) | OPRM1OPRL1OPRD1OPRK1NPSR1 | |
| SCHEMBL2656183 | 0.68 | CYP2D6 (0.55) | OPRM1OPRL1OPRD1OPRK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER INC | 2009-03-12 | — | — | US | disclosed |
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER INC | 2009-03-12 | — | — | US | disclosed |
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER INC | 2009-03-12 | — | — | US | disclosed |
| EP-1957448-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | Pfizer Products Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007060526-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007060526-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069287-A1 | SUBSTITUTED AZACYCLOALKANES USEFUL FOR TREATING CNS CONDITIONS | BACE2, BACE1, PMP22 | OPRM1 2303/4885OPRL1 1756/4885OPRD1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.